Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy

It remains unclear whether sequential assessment of hepatitis B virus (HBV) load during lamivudine therapy can predict the loss of hepatitis B e antigen or emergence of drug‐resistant variants. Therefore, a longitudinal study was carried out in 28 consecutive patients with chronic hepatitis B who st...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2001-12, Vol.65 (4), p.659-663
Main Authors: Zöllner, Bernhard, Schäfer, Peter, Feucht, Heinz-Hubert, Schröter, Matthias, Petersen, Jörg, Laufs, Rainer
Format: Article
Language:English
Subjects:
Administration, Oral
Adolescent
Adult
Aged
Antiviral Agents - therapeutic use
Biological and medical sciences
Cohort Studies
DNA, Viral - analysis
Drug Resistance, Viral
Female
Fundamental and applied biological sciences. Psychology
HBV
hepatitis B e antigen
Hepatitis B e Antigens - blood
Hepatitis B virus
Hepatitis B virus - drug effects
Hepatitis B virus - immunology
Hepatitis B virus - isolation & purification
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - virology
Humans
lamivudine
Lamivudine - therapeutic use
Male
Microbiology
Middle Aged
Mutation
Polymerase Chain Reaction
resistance
seroconversion
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It remains unclear whether sequential assessment of hepatitis B virus (HBV) load during lamivudine therapy can predict the loss of hepatitis B e antigen or emergence of drug‐resistant variants. Therefore, a longitudinal study was carried out in 28 consecutive patients with chronic hepatitis B who started lamivudine therapy for a median of 12 months (range, 6–31). HBV DNA copy numbers were determined at 3‐month intervals. From month 6 onward, HBV viral load below the detection limit of the PCR was predictive of the loss of envelope antigen (P = 0.043). Continuously detectable HBV DNA during the first 12 months of treatment indicated emergence of drug‐resistant variants (P = 0.034). These data suggest that the goal of lamivudine therapy should be complete suppression of serum HBV DNA. J. Med. Virol. 65:659–663, 2001. © 2001 Wiley‐Liss, Inc.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.2087